Vimian Group AB (publ) (VIMIAN) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Vimean's second quarter earnings call 2026. I'm Ali Taybach, Group CEO, and together with me I have our CFO Khalil Ansattabai Budhi presenting our results for the second quarter. We at Vimean continue building upon a good start of the year and report a second quarter with strong revenue and earnings growth as well as margin expansion. Our double-digit growth in the quarter is well ahead of the global animal health market coupled with strong adjusted EBITDA growth. We have also closed four acquisitions here today and continue to advance our M&A pipeline with active discussions across all four segments. We've also achieved recognition for our ESG achievements with a new AAA rating with MSCI. Turning to the numbers a bit more in detail, we report 17% revenue growth and reach 121.6 million euros in revenue in the second quarter. Organic growth was 12% with double-digit growth in specialty pharma, medtech and veterinary services, our three largest segments. 6% contribution from acquisitions and we had a 1% negative impact from currency movements. Adjusted EBITDA grew 17% to 29.7 million with strong earnings Growth ACROSS ALL FOUR SEGMENTS. MARGIN IMPROVED TO 24.5% DRIVEN BY THE CONSOLIDATION OF ACQUIRED BUSINESSES IN MEDTECH DENTAL SEGMENT. MOVING INTO SPECIALTY PHARMA, SPECIALTY PHARMA DELIVERS ANOTHER STRONG QUARTER WITH ORGANIC GROWTH OF 14%. ALL FOUR THERAPEUTIC AREAS DELIVER SOLID GROWTH AND THE STRONGEST CONTRIBUTION IN THIS QUARTER COMES FROM SPECIALTY PHARMACEUTICALS AND SPECIALIZED NUTRITIONS. In Specialized Nutrition, we completed another successful sales campaign together with a US retailer. A similar campaign took place in the third quarter of 2025. These campaigns make growth vary between quarters, but the underlying business momen...